Epinephrine promotes COX-2-dependent immune suppression in myeloid cells and cancer tissues

Highlights • Inflammation promotes catecholamine-driven immune suppression. • COX-2 blockade prevents the induction of suppressive factors by epinephrine. • COX-2 blockade counteracts suppressive activity of epinephrine-treated macrophages. • Our data suggest that COX-2 blockade may reduce the immun...

Full description

Saved in:
Bibliographic Details
Published in:Brain, behavior, and immunity behavior, and immunity, 2017-05, Vol.62, p.78-86
Main Authors: Muthuswamy, Ravikumar, Okada, Nana J, Jenkins, Frank J, McGuire, Kandace, McAuliffe, Priscilla F, Zeh, Herbert J, Bartlett, David L, Wallace, Callen, Watkins, Simon, Henning, Jill D, Bovbjerg, Dana H, Kalinski, Pawel
Format: Article
Language:English
Subjects:
Allergy and Immunology
Animals
Breast cancer
cAMP
Celecoxib - pharmacology
Cell Proliferation - drug effects
Colon cancer
CTLs
Cyclooxygenase 2 - metabolism
Cyclooxygenase 2 Inhibitors - pharmacology
Epinephrine
Epinephrine - pharmacology
Female
Humans
IDO
Immune suppression
Indoleamine-Pyrrole 2,3,-Dioxygenase - metabolism
Inflammation
Interleukin-10 - metabolism
Macrophages - drug effects
Macrophages - immunology
Macrophages - metabolism
Mammary Neoplasms, Experimental - immunology
Mammary Neoplasms, Experimental - metabolism
Mice
Myeloid Cells - drug effects
Myeloid Cells - immunology
Myeloid Cells - metabolism
Prostaglandins
Psychiatry
Stress
Suppressive macrophages
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Inflammation promotes catecholamine-driven immune suppression. • COX-2 blockade prevents the induction of suppressive factors by epinephrine. • COX-2 blockade counteracts suppressive activity of epinephrine-treated macrophages. • Our data suggest that COX-2 blockade may reduce the immunosuppressive effects of psychologic stress.
ISSN:0889-1591
1090-2139
1090-2139
DOI:10.1016/j.bbi.2017.02.008